Reuters -- Sanofi-Aventis’s experimental chemotherapy drug Jevtana increases survival by 30 percent in men with prostate cancer whose tumours no longer respond to standard treatment, according to new research.
Reuters -- Sanofi-Aventis’s experimental chemotherapy drug Jevtana increases survival by 30 percent in men with prostate cancer whose tumours no longer respond to standard treatment, according to new research.
